1.21
Schlusskurs vom Vortag:
$1.24
Offen:
$1.27
24-Stunden-Volumen:
227.52K
Relative Volume:
0.72
Marktkapitalisierung:
$26.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.29M
KGV:
-1.7286
EPS:
-0.7
Netto-Cashflow:
$-6.47M
1W Leistung:
-6.92%
1M Leistung:
-12.32%
6M Leistung:
-9.70%
1J Leistung:
-19.33%
NanoViricides Inc Stock (NNVC) Company Profile
Firmenname
NanoViricides Inc
Sektor
Branche
Telefon
203-937-6137
Adresse
1 Controls Drive, Shelton, CT
Vergleichen Sie NNVC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
NNVC
NanoViricides Inc
|
1.21 | 26.74M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | Alliance Global Partners | Buy |
| 2015-02-11 | Eingeleitet | Midtown Partners | Strong Buy |
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
Is NanoViricides Inc. stock a top momentum playRisk Management & Intraday High Probability Alerts - Улправда
Is NanoViricides Inc. stock positioned for secular growthProfit Target & High Return Trade Opportunity Guides - Улправда
Is NanoViricides Inc. stock cheap at current valuationMarket Performance Recap & Weekly Return Optimization Plans - Улправда
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Asbury Park Press
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
NanoViricides advances Phase 2 trials for broad-spectrum antiviral NV-378 in $17B market: analysts - Proactive financial news
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Lubbock Avalanche-Journal
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Enterprise News
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - Worcester Telegram
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - SouthCoastToday.com
NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - SouthCoastToday.com
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - Siskiyou Daily News
Belarus frees Nobel laureate Ales Bialiatksi and opposition figure Maria Kolesnikova from prison, rights group confirms - Barchart.com
Applied Digital, Benchmark, Knowles, Cognex, and Flex Stocks Trade Down, What You Need To Know - Barchart.com
Shootin' the Bull about wait and see - Barchart.com
2 Small-Cap Biotechs That Could Reward Patient Investors - Investing.com
EU indefinitely freezes Russian assets to stop Moscow-friendly Hungary and Slovakia from vetoing their use for Ukraine - Barchart.com
2 Small-Cap Biotechs That Could Reward Patient Investors - MarketBeat
Is Clorox Stock Underperforming the S&P 500? - Barchart.com
Is J.B. Hunt Transport Services Stock Outperforming the Dow? - Barchart.com
Americans, including many in Trump’s base, overwhelmingly see higher holiday prices than normal, an AP-NORC poll finds - Barchart.com
Is Hologic Stock Outperforming the Nasdaq? - Barchart.com
How Is VeriSign’s Stock Performance Compared to Other Software Stocks? - Barchart.com
NanoViricides Holds 2025 Annual Stockholders Meeting - MSN
US sanctions 3 nephews of Venezuelan President Maduro as Trump further ramps up pressure on South American nation - Barchart.com
This AI Stock Has 45% Upside Potential and No One Is Talking About It Yet - Barchart.com
Stocks in play: Goodfood Market Corp. - Barchart.com
How Is Best Buy's Stock Performance Compared to Other Specialty Retail Stocks? - Barchart.com
Corpay Stock: Is CPAY Underperforming the Technology Sector? - Barchart.com
1 Profitable Stock to Target This Week and 2 We Avoid - Barchart.com
3 Reasons EYE is Risky and 1 Stock to Buy Instead - Barchart.com
3 Reasons to Sell SJM and 1 Stock to Buy Instead - Barchart.com
Why Inspire Medical Systems (INSP) Stock Is Up Today - Barchart.com
Is Veralto Corporation Stock Underperforming the S&P 500? - Barchart.com
Is Steel Dynamics Stock Outperforming the Dow? - Barchart.com
Is PTC Stock Underperforming the Nasdaq? - Barchart.com
Is Invitation Homes Stock Underperforming the Dow? - Barchart.com
Is Teradyne Stock Outperforming the Nasdaq? - Barchart.com
Is Cardinal Health Stock Outperforming the Nasdaq? - Barchart.com
Chewy (NYSE:CHWY) Surprises With Q3 CY2025 Sales - Barchart.com
Is FirstEnergy Stock Underperforming the S&P 500? - Barchart.com
How Is Rollins’ Stock Performance Compared to Other Cyclical Stocks? - Barchart.com
GBPUSD Extends Rally As Bullish Impulse Builds - Barchart.com
3 Inflated Consumer Stocks That Concern Us - Barchart.com
Commerce (CMRC): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
AeroVironment (NASDAQ:AVAV) Beats Q3 CY2025 Sales Expectations But Stock Drops - Barchart.com
Apple Stock Marks a Solid Comeback. Is AAPL a Buy, Sell, or Hold for 2026? - Barchart.com
Marvell Soars 32% in 3 Months — Is MRVL Stock a Buy, Sell, or Hold? - Barchart.com
AeroVironment: Fiscal Q2 Earnings Snapshot - Barchart.com
Why Are Revolve (RVLV) Shares Soaring Today - Barchart.com
Upwork (UPWK) Stock Is Up, What You Need To Know - Barchart.com
Finanzdaten der NanoViricides Inc-Aktie (NNVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):